<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146456</url>
  </required_header>
  <id_info>
    <org_study_id>Colloid_tranexamic acid</org_study_id>
    <nct_id>NCT02146456</nct_id>
  </id_info>
  <brief_title>Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion</brief_title>
  <official_title>The Effect of Tranexamic Acid on Blood Coagulation After Colloid Infusion During Surgery: Rotational Thromboelastography Measurement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <brief_summary>
    <textblock>
      Colloid solution is generally used to maintain intravascular volume. It is reported to impair&#xD;
      blood coagulation in vivo and in vitro more than crystalloid does by prolonging coagulation&#xD;
      time and decreasing clot strength. The formed fibrin clot is more vulnerable for fibrinolysis&#xD;
      in a case of using colloid. Dilution of plasmin in vitro with colloid enhances fibrinolysis&#xD;
      primarily by diminishing Î±2-antiplasmin-plasmin interaction.&#xD;
&#xD;
      Tranexamic acid is an antifibrinolytics that competitively inhibits the activation of&#xD;
      plasminogen, by binding to specific site of both plasminogen and plasmin, a molecule&#xD;
      responsible for the degradation of fibrin, a protein that forms the framework of blood clot.&#xD;
      It is used to treat or prevent excessive blood loss during surgery and in other medical&#xD;
      conditions. Gastrointestinal effect, dizziness, fatigue, headache, hypersensitivity reaction,&#xD;
      or potential risk of thrombosis is reported as the adverse effect of tranexamic acid.&#xD;
&#xD;
      We hypothesized that inhibition of plasmin by tranexamic acid after colloid administration&#xD;
      can improve the colloid-induced clot strength impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rotational thromboelastography</measure>
    <time_frame>30 minutes before starting an operation and 30 minutes after finishing an operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>30 minutes before starting an operation and 30 minutes after finishing an operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet</measure>
    <time_frame>30 minutes before starting an operation and 30 minutes after finishing an operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International normalized ratio of prothrombin time</measure>
    <time_frame>30 minutes before starting an operation and 30 minutes after finishing an operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>30 minutes before starting an operation and 30 minutes after finishing an operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>30 minutes before starting an operation and 30 minutes after finishing an operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Avascular Necrosis of Femoral Head</condition>
  <condition>Degenerative Arthritis of Hip</condition>
  <arm_group>
    <arm_group_label>Colloid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.&#xD;
In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing total hip replacement arthroplasty, who are diagnosed with the&#xD;
             avascular necrosis of femoral head or degenerative arthritis of hip&#xD;
&#xD;
          -  American Society of Anesthesiologist I or II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving an intraoperative transfusion&#xD;
&#xD;
          -  Patients receiving thrombin&#xD;
&#xD;
          -  Patients having venous thromboembolism&#xD;
&#xD;
          -  Patients having renal or hepatic disease&#xD;
&#xD;
          -  Patients having coagulopathy&#xD;
&#xD;
          -  Patient having heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Pf</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

